Sage Therapeutics, Inc. (NASDAQ:SAGE) receives a consensus price target of $16.06 from analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report ) has received a consensus recommendation of “Reduce” from the nineteen analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and one has issued a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $16.06.

SAGE has been the subject of several recent research reports. Mizuho cut their price target on Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Robert W. Baird decreased their price objective on shares of Sage Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Thursday, July 25th. JPMorgan Chase & Co. cut their price target on shares of Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Canaccord Genuity Group dropped their target price on shares of Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating on the stock in a research note on Friday, April 26th. Finally, Royal Bank of Canada cut their price objective on shares of Sage Therapeutics from $26.00 to $15.00 and set a “sector perform” rating for the company in a research report on Friday, April 26.

Check out our latest analysis of Sage Therapeutics

Sage Therapeutics Stock Performance

NASDAQ SAGE opened at $8.14 on Thursday. The firm has a market cap of $496.95 million, a price-to-earnings ratio of -0.97 and a beta of 0.90. Sage Therapeutics has a one year low of $7.70 and a one year high of $28.26. The company’s 50-day moving average price is $10.58 and its 200-day moving average price is $14.93.

Sage Therapeutics (NASDAQ:SAGE – Get Free Report ) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The business had revenue of $8.65 million during the quarter, compared to analyst estimates of $8.85 million. During the same period in the previous year, the company earned EPS of ($2.68). Sage Therapeutics’ revenue was up 249.8% year-over-year. sell-side analysts forecast that Sage Therapeutics will post -6.43 EPS for the current fiscal year.

Hedge funds weigh Sage Therapeutics

Institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC boosted its holdings in shares of Sage Therapeutics by 245.3% in the second quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 2,782 shares during the last quarter. Lazard Asset Management LLC bought a new stake in Sage Therapeutics in the first quarter valued at $127,000. Virtu Financial LLC purchased a new position in shares of Sage Therapeutics in the 1st quarter valued at $187,000. China Universal Asset Management Co. Ltd. grew its position in shares of Sage Therapeutics by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,554 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 4,617 shares during the last quarter. Finally, Quest Partners LLC boosted its holdings in shares of Sage Therapeutics by 14.5% in the second quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after acquiring an additional 1,486 shares during the period. 99.22% of shares are held by institutional investors.

Sage Therapeutics Company Profile

(Get a free report

Sage Therapeutics, Inc, a biopharmaceutical company, develops and markets drugs for brain health. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

See Also

Get news and ratings for Sage Therapeutics daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sage Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.